Embecta Aktie News

PARSIPPANY, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- On World Diabetes Day, embecta Corp. (“embecta”) (Nasdaq: EMBC), the largest manufacturer of insulin injection devices in the world, today announced a significant expansion of its partnership with Direct Relief, the leading humanitarian aid organization and largest charitable insulin provider in the United States.

PARSIPPANY, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal fourth quarter and full year 2025 financial results and provide an operational update, including preliminary fiscal year 2026 fi...

YCharts recently began posting the entire collection of Standard and Poors Indexes: 500 Large-Caps; 400 Mid-Caps; 600 Small-Caps. This article provides an October update to the S&P600 Small-Cap Top 40 dividend dogs by yield. All 40 of current S&P600 top yield small-cap stocks pay dividends. As of 10/20/25 yields ranged 4.12%-9.32% annually. 38 by broker-target-price-estimates ranged 0.39%-53.06...

Embecta's restructuring and discontinuation of the patch pump system have significantly improved profitability, enabling substantial cost savings and debt reduction. The company is refocusing on core strengths, expanding into drug delivery and chronic care, and leveraging new pharma partnerships for broader growth. Financial guidance shows strong adjusted EPS and EBITDA margin growth, with cost...

EMBC's strong Q3 results and improved profitability highlight management's effective cost controls, despite revenue growth being driven by one-off events. The new strategic direction focuses on strengthening the core insulin delivery business and expanding into adjacent markets while aggressively deleveraging. Short-term revenue headwinds persist due to a shrinking core market, but EMBC's reput...

PARSIPPANY, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events:

Embecta Corp. (NASDAQ:EMBC ) Q3 2025 Earnings Conference Call August 8, 2025 8:00 AM ET Company Participants Devdatt Kurdikar - President, CEO & Director Jacob P. Elguicze - Senior VP & CFO Pravesh Khandelwal - VP & Head of Investor Relations Conference Call Participants Anthony Charles Petrone - Mizuho Securities USA LLC, Research Division Gracia Leydon Mahoney - BofA Securities, Research Divi...

PARSIPPANY, N.J., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and nine month periods ended June 30, 2025.